Synthetic Metabolic and Genetic Networks for Medical Diagnosics

Cancer Clinical Trial

— SynBioDiag  

Official title:

Development of Synthetic Metabolic and Genetic Networks for the Detection of Urogenital Cancers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04518072
• Other study ID #: RECHMPL18_0404
• Secondary ID: 2019-A00234-53
• Status: Recruiting
• Start date: January 6, 2021
• Est. completion date: July 6, 2027

Study information

• Verified date: January 2024
• Source: University Hospital, Montpellier
• Contact: Jerome SOLASSOL, PHD
• Phone: 04.67.33.58.76
• Email: j-solassol[@]chu-montpellier.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a category 3 human study, prospective, comparative, in parallel groups. A comparative qualitative and quantitative analysis of several markers in 250 samples is proposed.

Description:

The assumption is that researchers can engineer synthetic metabolic and genetic networks to expand the panel of molecules that are currently known to be detected by natural systems. The investigators also hypothesize synthetic metabolic and genetic networks can be tuned for decisions making and in particular to diagnose diseases from biomarkers detections.

This project proposes for the first time a hybrid analogue / digital solution for the multiplexed detection of biomarkers using bacterial and paper-based biosensors. Biosensors can be designed using analog or digital devices. Digital devices in synthetic and natural systems are noise-resistant and useful for decision-making. Analog devices are useful for signal transmission and processing. Here the investigators take advantage of signal transmission and processing via analog transducers and adders, and then decision-making via genetic switches. Such a hybrid analogue / digital approach has not yet been developed for biosensing. Another novelty of the project is to use synthetic metabolic pathways to develop analog devices. The advantage in term of treatment, for example, consists in the fact that the speed of enzymatic reactions in an analog adder far exceeds the speed of gene expression required to create a genetic logic matrix; it becomes even more pronounced when the devices are connected in series. The methodology will be illustrated for the detection of biomarkers of prostate tumors, but it is broad enough to be applicable to other diagnoses. The choice to develop biosensors for prostate disease is of practical relevance since the current screening strategy (based on PSA measurement) can lead to overdiagnosis and cannot differentiate between patients with aggressive tumors and those with an indolent illness.This study propose to mainly develop a bacterial and paper-based biosensor system

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: July 6, 2027
• Est. primary completion date: July 6, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men aged over 18

• Informed, written consent of the patient for the biological collection

• Subject affiliated to a French social security scheme or beneficiary of such a scheme

Patients specific inclusion criteria :

• Admitted to care prostate disease or suspicion of prostate cancer and with a positive or negative PSA blood result

Controls specific inclusion criteria :

• Man free from all prostate or bladder pathologies

Exclusion Criteria:

• Patient under legal protection

• Persons deprived of their liberty, protected adults or vulnerable persons

• Participants may withdraw their consent at any time and for any reason whatsoever without incurring any negative consequences without change in their usual care

Controls specific non-inclusion criteria :

• Patient with current prostatic or urinary infection

• History of treatment for prostate cancer other than surveillance management

Related Conditions & MeSH terms

• Cancer
• Prostate

Intervention

Other:
• Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)
assessed biomarker in clinical samples

Locations

Country	Name	City	State
France	Clinique Beau Soleil	Montpellier
France	University Hospital	Montpellier	Hérault

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Montpellier	CBS, MICALIS

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnosis of adenocarcinoma of the prostate	Number of patients clinically diagnosed with prostate adenocarcinoma	Up to three years
Secondary	Investigational biomarker panel for diagnosis / Prostatic specific antigen	Biospecimen retention: blood serum and urine (unit mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / Creatinine	Biospecimen retention: blood serum and urine (unit µmol/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / Sarcosine	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / Spermine	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / Ornithine	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / Choline	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis /Taurine	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / Fumarate	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / Serotonin	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / Putrescine	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis /ribitol	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / inositol	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis / 2-oxoglutarate	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline
Secondary	Investigational biomarker panel for diagnosis /citrate	Biospecimen retention: blood serum and urine (unit: mg/l)	Baseline